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The immunoreceptor strategy is based on grafting of T
cells with recombinant T cell receptor molecules that con-
sist extracellularily of a scFv domain for MHC-independ-
ent antigen binding and intracellularily of the CD3 ζ- or
FcεRI γ-signalling domain for cellular activation. Upon
binding to antigen-positive cells, grafted T cells are acti-
vated, secrete IFN-γ, and lyse specifically antigen-positive,
but not antigen-negative target cells. During the last years,
we generated a panel of immunoreceptors with specficity
for "tumor associated antigens" as targets for use in adop-
tive immunotherapy of malignant diseases: CEA, CA72-4,
CA19-9 for gastrointestinal carcinomas, CD30 for Hodg-
kin's lymphoma and cutaneous T cell lymphoma, HMW-
MAA and melanotransferrin for melanoma, and ErbB2 for
a variety of carcinomas [1,2]. T cells taken from the
peripheral blood of tumor patients and grafted with the
appropriate immunoreceptor mediate a highly efficient
immune response towards autologous, antigen expressing
target cells in vitro [3].
One of the major advantages of the immunoreceptor
strategy lies in the modular compositon of the receptor
molecule. However, little is known about the impact of
the individual receptor modules on cellular activation in
a complex immunological context. We have identified
several items that affect the efficacy of receptor mediated
cellular activation including: the signalling domain that
affects the stability of immunoreceptor expression and
function in T cells [4]; the affinity of the scFv domain that
affects the efficacy of T cell activation; B7-1 and B7-2 cos-
timulation that affects the quality of T cell activation [5-7].
The high complexity of the recognition and signalling
process makes it unlikely that a universal configuration of
the immunoreceptor exists. The design of the receptor
molecule, however, has major impact on the stability and
function in T cells and thereby on the efficacy of adoptive
immunotherapy.
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